Physician profile
David C Garrett
NPI 1265489421
$335.13
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.09 · 2021: $153 · 2022: $88.96.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $124.94 | 2021 | |
| Genentech USA, INC. | $70.36 | 2019 | |
| Corium, LLC | $40.54 | 2022 | |
| Abbvie INC. | $19.26 | 2022 | |
| Currax Pharmaceuticals LLC | $15.74 | 2022 | |
| Lilly USA, LLC | $15.44 | 2021 | |
| Novo Nordisk INC | $13.42 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.70 | 2021 | |
| Merck Sharp & Dohme LLC | $12.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.